# US 2021/0332353 A1 · Argonaute protein mutant and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332353 A1
- Document ID: US20210332353A1
- Status: Published application
- Kind: A1
- Application number: 16/978,428
- Filed: 2019-01-03
- Published: 2021-10-28
- Earliest claimed: 2018-03-06
- Assignees: Berry Genomics Co., Ltd.
- Applicants: Berry Genomics Co., Ltd
- Inventors: Jianguang ZHANG; Aiping MAO
- Web page: https://patentgrep.com/patent/US20210332353A1

## CPC

- C12N 15/1093: {General methods of preparing gene libraries, not provided for in other subgroups}
- C40B 40/06: Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C07K 14/195: from bacteria
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C40B 50/06: Biochemical methods, e.g. using enzymes or whole viable microorganisms
- C07K 2319/85: containing an RNA binding domain
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to a mutant of Argonaute protein lacking a DNA cleavage activity but having a DNA binding activity, wherein the mutation of the mutant is located in a PIWI domain. The present invention also relates to a use based on the protein mutant, especially in enrichment of a target DNA and construction of sequence libraries. Therefore, the present invention also relates to a method for enrichment of a target DNA, comprising the following steps: (a) designing a guide sequence for a specific sequence in the target DNA; (b) binding the mutant according to the present invention, the guide sequence and the target DNA to obtain a mutant-guide sequence-target DNA ternary complex; (c) capturing the mutant-guide sequence-target DNA ternary complex through a capture medium; and (d) separating the target DNA from the captured mutant-guide sequence-target DNA ternary complex to obtain an enriched target DNA.

## Claims

### Claim at position 1

1-39. (canceled)

### Claim 40

A mutant of Argonaute protein, having a DNA binding activity but lacking a DNA cleavage activity, wherein the mutation of the mutant is located in a PIWI domain.

### Claim 41 (depends on 40)

The mutant of claim 40, wherein the Argonaute protein is derived from Marinitoga, Thermotoga, Pyrococcus, Methanocaldococus, Rhodobacter, Aquifex, Archaeoglobus, or Thermus.

### Claim 42 (depends on 40)

The mutant of claim 40, wherein the Argonaute protein is derived from Pyrococcus furiosus, Thermus thermophiles, Methanocaldococus jannaschii, Marinitoga piezophila, Rhodobacter sphaeroides, Aquifex aeolicus, Archaeoblobus fulgidus or Thermotoga profunda.

### Claim 43 (depends on 40)

The mutant of claim 40, wherein the amino acid sequence of the Argonaute protein is selected from SEQ ID NOs: 1-8.

### Claim 44 (depends on 43)

The mutant of claim 43, wherein the mutant comprises one or more mutations selected from the group consisting of:
substitution of amino acid residues at positions 558, 596, 628 and 745 of SEQ ID NO: 1, and of amino acid residues at the positions corresponding to the above positions, or
deletion of amino acid at positions 628-770 of SEQ ID NO: 1, and of amino acid residues at the positions corresponding to the above positions.

### Claim 45 (depends on 44)

The mutant of claim 44, wherein the substitution is alanine or glutamic acid substitution.

### Claim 46 (depends on 40)

The mutant of claim 40, wherein the mutant further comprises mutations located in the following domains: N-terminal domain and PAZ domain.

### Claim 47 (depends on 40)

A method for enrichment of a target DNA comprising the following steps:
(a) designing a guide sequence for a specific sequence in the target DNA;
(b) binding the mutant of claim 40, the guide sequence and the target DNA to obtain a mutant-guide sequence-target DNA ternary complex;
(c) capturing the mutant-guide sequence-target DNA ternary complex through a capture medium;
(d) separating the target DNA from the captured mutant-guide sequence-target DNA ternary complex to obtain an enriched target DNA.

### Claim 48 (depends on 47)

The method of claim 47, wherein the step (b) further comprises the following steps:
(b1) binding the mutant according to the present invention with a guide sequence to obtain a mutant-guide sequence binary complex;
(b2) binding a dAgo-guide sequence binary complex with the target DNA sequence to obtain a mutant-guide sequence-target DNA ternary complex.

### Claim 49 (depends on 47)

The method of claim 47, wherein the guide sequence is an RNA or a DNA.

### Claim 50 (depends on 47)

The method of claim 47, wherein the guide sequence is a single stranded RNA (ssRNA) or a single stranded DNA (ssDNA).

### Claim 51 (depends on 47)

The method of claim 47, wherein the guide sequence comprises nucleotide modifications.

### Claim 52 (depends on 51)

The method of claim 51, wherein the modification is 5′ phosphorylation or 5′ hydroxylation.

### Claim 53 (depends on 47)

The method of claim 47, wherein the guide sequence has a length of 15-25 nucleotides.

### Claim 54 (depends on 47)

The method of claim 47, wherein the guide sequence is substantially complementary to the specific sequence in the target DNA.

### Claim 55 (depends on 47)

The method of claim 47, wherein the capture medium is magnetic beads.

### Claim 56 (depends on 47)

The method of claim 47, wherein the capture medium carries a capture tag capable of binding to the specific tag carried by the mutant.

### Claim 57 (depends on 40)

A kit comprising the mutant of claim 40.

### Claim 58 (depends on 57)

The kit of claim 57, further comprising a guide sequence and a capture medium.

### Claim 59 (depends on 58)

The kit of claim 58, wherein the guide sequence is an RNA or a DNA.
